News

November 28, 2017November 28, 2017

Weill Cornell Medicine Gets $2.1 Million to Study Gene’s Role in Lung and Kidney Fibrosis

Weill Cornell Medicine in New York City has received a $2.1 million government grant to study a mechanism underlying lung and kidney scarring. The National Heart, Lung and Blood Institute grant will allow ... Read more

November 27, 2017November 27, 2017

New York’s Montefiore Einstein Center Launches Lung Transplant Program

COPD, Cystic Fibrosis, Idiopathic Pulmonary Fibrosis, News

New York City’s Montefiore Einstein Center for Heart & Vascular Care has received interim approval from the United Network for Organ Sharing (UNOS) to launch its new lung transplant program. Lung transplant ... Read more

November 22, 2017November 22, 2017

PF Foundation Summit Highlights Roles of Care, Research, and Technology

Idiopathic Pulmonary Fibrosis, News

The Pulmonary Fibrosis Foundation’s PFF Summit 2017 Nov. 9-11 in Nashville, Tennessee, recorded an unprecedented number of attendees, including physicians, researchers, patients, caregivers and industry professionals. The lung disease summit takes place ... Read more

November 21, 2017November 21, 2017

Many European IPF Patients Are Not Receiving Anti-lung-scarring Therapies, Survey Indicates

Idiopathic Pulmonary Fibrosis, News

Despite anti-fibrotic therapies’ ability to help idiopathic pulmonary fibrosis patients, more than half of Europeans who have the disease are not receiving them. That’s because a lot fo physicians are ... Read more

November 20, 2017November 20, 2017

FDA Approves Fasenra for Severe Asthma Stemming from Immune Cell Glut

Asthma, News

The U.S. Food and Drug Administration has approved Fasenra (benralizumab) as an add-on maintenance treatment for people 12 years and older with severe asthma. In this case, the authorization is ... Read more

November 16, 2017November 16, 2017

Ofev Slows Scarring in Pulmonary Fibrosis Patients’ Lungs, Phase 3b Trial Shows

Idiopathic Pulmonary Fibrosis, News

Boehringer Ingelheim’s Ofev (nintedanib) slows scarring in idiopathic pulmonary fibrosis patients’ lungs, a Phase 3b trial indicates. The company used an imaging technique to check on Ofev’s anti-fibrotic properties. It was the ... Read more

November 15, 2017November 15, 2017

Canadian Association Conducting Purple Challenge Campaign During PH Awareness Month

News, Pulmonary Hypertension

The Pulmonary Hypertension Association of Canada is conducting a Life in Purple Challenge this month as part of its efforts to mark November as Pulmonary Hypertension Awareness Month. The goal is to raise ... Read more

November 14, 2017November 14, 2017

ATS Foundation, Boehringer Ingelheim Fund New Fellowship on IPF Research

Idiopathic Pulmonary Fibrosis, News

The American Thoracic Society (ATS) Foundation and Boehringer Ingelheim have jointly launched a new research fellowship in idiopathic pulmonary fibrosis (IPF), aiming to grant young investigators $100,000 over a two-year period from ... Read more

November 13, 2017November 13, 2017

Esbriet Safe but Less Effective in Severe IPF Patients After 6 Months of Treatment, Small Study Says

Idiopathic Pulmonary Fibrosis, News

A retrospective real-world study found that the benefits of Esbriet (pirfenidone) in people with advanced idiopathic pulmonary fibrosis (IPF) appeared to diminish after six months of treatment, although side effects were ... Read more

November 9, 2017November 9, 2017

Esbriet Treatment Helps Reduce Cough in IPF Patients, European Study Shows

Idiopathic Pulmonary Fibrosis, News

Treatment with Esbriet (pirfenidone) significantly reduced cough by 34 percent in patients with idiopathic pulmonary fibrosis (IPF), along with cough severity, a new 12-week study shows. The study, “Effect of pirfenidone ... Read more